Evidence map›Paper›PMID 39606240›Full record

ArticleFrontiers in immunology2024

Transcriptomics profiling of the non-small cell lung cancer microenvironment across disease stages reveals dual immune cell-type behaviors.

Marcelo Hurtado, Leila Khajavi, Abdelmounim Essabbar, Michael Kammer, Ting Xie, Alexis Coullomb, Anne Pradines, Anne Casanova, Anna Kruczynski, Sandrine Gouin and 17 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Marcelo Hurtado *CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Leila Khajavi *CRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Abdelmounim EssabbarCRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Michael KammerCRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Ting XieCRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Alexis CoullombCRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Anne PradinesCRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Anne CasanovaCRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Anna KruczynskiInstitut de Recherche Pierre Fabre, Toulouse, France.
Sandrine GouinPulmonology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France.
Estelle ClermontCRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Léa BoutilletCRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Maria Fernanda SenosainDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Yong ZouDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Shillin Zhao *Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, United States.
Prosper BurqData Science, Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
Abderrahim MahfoudiInstitut de Recherche Pierre Fabre, Toulouse, France.
Jerome BesseInstitut de Recherche Pierre Fabre, Toulouse, France.
Pierre LaunayInstitut de Recherche Pierre Fabre, Toulouse, France.
Alexandre PassioukovInstitut de Recherche Pierre Fabre, Toulouse, France.
Eric ChetailleInstitut de Recherche Pierre Fabre, Toulouse, France.
Gilles FavreCRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Fabien MaldonadoDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Francisco CruzaleguiInstitut de Recherche Pierre Fabre, Toulouse, France.
Olivier DelfourInstitut de Recherche Pierre Fabre, Toulouse, France.
Julien MazièresCRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.
Vera PancaldiCRCT, Université de Toulouse, Institut national de la santé et de la recherche médicale (Inserm), Centre national de la recherche scientifique (CNRS), Université Toulouse III-Paul Sabatier, Centre de Recherches en cancérologie de Toulouse, Toulouse, France.

Funding

Validation of Biomarkers of Risk for the Early Detection of Lung CancerU01CA152662 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DEPPEN, STEPHEN, GROGAN, ERIC L · 2010 to 2025
$12.8M
Interdisciplinary Training Program in Lung ResearchT32HL094296 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ray Stokes Peebles · 2008 to 2026
$6.3M
Cellular, molecular and quantitative imaging analysis of screening-detected lung adenocarcinomaU01CA196405 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MALDONADO, FABIEN · 2015 to 2020
$5.4M
NCI NIH HHS U01 CA152662NCI NIH HHS U01 CA196405NHLBI NIH HHS T32 HL094296
6 · The paper itself

Abstract

Background: Lung cancer is the leading cause of cancer death worldwide, with poor survival despite recent therapeutic advances. A better understanding of the complexity of the tumor microenvironment is needed to improve patients' outcome. Methods: We applied a computational immunology approach (involving immune cell proportion estimation by deconvolution, transcription factor activity inference, pathways and immune scores estimations) in order to characterize bulk transcriptomics of 62 primary lung adenocarcinoma (LUAD) samples from patients across disease stages. Focusing specifically on early stage samples, we validated our findings using an independent LUAD cohort with 70 bulk RNAseq and 15 scRNAseq datasets and on TCGA datasets. Results: Through our methodology and feature integration pipeline, we identified groups of immune cells related to disease stage as well as potential immune response or evasion and survival. More specifically, we reported a duality in the behavior of immune cells, notably natural killer (NK) cells, which was shown to be associated with survival and could be relevant for immune response or evasion. These distinct NK cell populations were further characterized using scRNAseq data, showing potential differences in their cytotoxic activity. Conclusion: The dual profile of several immune cells, most notably T-cell populations, have been discussed in the context of diseases such as cancer. Here, we report the duality of NK cells which should be taken into account in conjunction with other immune cell populations and behaviors in predicting prognosis, immune response or evasion.

Indexed as

Carcinoma, Non-Small-Cell LungGene Expression ProfilingKiller Cells, NaturalLung NeoplasmsTranscriptomeTumor MicroenvironmentAdenocarcinoma of LungComputational BiologyFemaleGene Expression Regulation, NeoplasticHumansMaleNeoplasm Stagingcell deconvolutionimmune landscapelung adenocarcinomanatural killer cellstranscription factor activity

Identifiers

PMID39606240
PMCPMC11600981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.